Skip to Content

Coronavirus information for Feinberg.

Download the full-sized PDF of Ticlopidine-, Clopidogrel-, and Prasugrel-associated thrombotic thrombocytopenic purpura: a 20-year review from the Southern Network on Adverse Reactions (SOAR)
Download the file

Actions

Download Analytics Citations

Export to: EndNote

Collections

This file is not currently in any collections.

Ticlopidine-, Clopidogrel-, and Prasugrel-associated thrombotic thrombocytopenic purpura: a 20-year review from the Southern Network on Adverse Reactions (SOAR) Open Access (recommended)

Descriptions

Resource type(s)
Article
Keyword
Ticlopidine
Clopidogrel
Prasugrel
Rights
Attribution 4.0 International

Creator
Jacob, Sony
Dunn, Brianne L.
Qureshi, Zaina, 1982-
Bandarenko, Nicholas
Kwaan, Hau C
Pandey, Dilip K.
McKoy, June M
Barnato, Sara E.
Winters, Jeffrey L.
Cursio, John F.
Weiss, Ivy M
Raife, Thomas J.
Carey, Patricia M.
Sarode, Ravindra
Kiss, Joseph E.
Danielson, Constance
Ortel, Thomas L. (Thomas Lee), 1957-
Clark, William F.
Rock, Gail
Matsumoto, Masanori, 1935-
Fujimura, Yoshihiro
Zheng, X. Long
Chen, Hao
Chen, Fei
Armstrong, John M.
Raisch, Dennis W.
Bennet, Charles L.
Abstract
Thienopyridine derivatives (ticlopidine, clopidogrel, and prasugrel) are the primary antiplatelet agents. Thrombotic thrombocytopenic purpura (TTP) is a rare drug-associated syndrome, with the thienopyridines being the most common drugs implicated in this syndrome. We reviewed 20 years of information on clinical, epidemiologic, and laboratory findings for thienopyridine-associated TTP. Four, 11, and 11 cases of thienopyridine- associated TTP were reported in the first year of marketing of ticlopidine (1989), clopidogrel (1998), and prasugrel (2010), respectively. As of 2011, the FDA received reports of 97 ticlopidine-, 197 clopidogrel-, and 14 prasugrel-associated TTP cases. Severe deficiency of ADAMTS-13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif member 13) was present in 80% and antibodies to 100% of these TTP patients on ticlopidine, 0% of the patients with clopidogrel-associated TTP (p < 0.05), and an unknown percentage of patients with prasugrel-associated TTP. TTP is associated with use of each of the three thienopyridines, although the mechanistic pathways may differ.
Original Bibliographic Citation
Jacob, S., Dunn, B. L., Qureshi, Z. P., Bandarenko, N., Kwaan, H. C., Pandey, D. K., . . . Bennett, C. L. (2012). Ticlopidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: a 20-year review from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost, 38(8), 845-853. doi:10.1055/s-0032-1328894
Publisher
Thieme Medical Publishers, Inc.
DigitalHub. Galter Health Sciences Library
Date Created
2012-10-30
Original Identifier
(PMID) 23111862
Language
English
Subject: MESH
Ticlopidine
Purpura, Thrombotic Thrombocytopenic
Thienopyridines
DOI
10.1055/s-0032-1328894
ARK
ark:/c8131/g3bk5p

File Details

File Properties
Mime type: application/pdf
File size: 8998.5 kB